BACKGROUND: Rhabdomyosarcoma (RMS) is divided into two major histological subtypes: alveolar (ARMS) and embryonal (ERMS), with most ARMS expressing one of two oncogenic genes fusing PAX3 or PAX7 with FOXO1 (P3F and P7F, respectively). The Children's Oncology Group (COG) carried out a multi-institutional clinical trial to evaluate the prognostic value of PAX-FOXO1 fusion status. METHODS: Study participants were treated on COG protocol D9803 for intermediate risk ARMS or ERMS using multi-agent chemotherapy, radiotherapy, and surgery. Central diagnostic pathology review and molecular testing for fusion genes were carried out on prospectively collected specimens. Event-free (EFS) and overall survival (OS) at 5 years were correlated with histological subtype and PAX-FOXO1 status. RESULTS:Of 616 eligible D9803 enrollees, 434 cases had adequate clinical, molecular, and pathology data for definitive classification as ERMS, ARMS P3F+ or P7F+, or ARMSn (without detectable fusion). EFS was worse for those with ARMS P3F+ (54%) and P7F+ (65%) than those with ERMS (77%; P < 0.001). EFS for ARMSn and ERMS were not statistically different (90% vs. 77%, P = 0.15). ARMS P3F+ had poorer OS (64%) than ARMS P7F+ (87%), ARMSn (89%), and ERMS (82%; P = 0.006). CONCLUSIONS: ARMSn has an outcome similar to ERMS and superior EFS compared to ARMS with either P3F or P7F, when given therapy designed for children with intermediate risk RMS. This prospective analysis supports incorporation of PAX-FOXO1 fusion status into risk stratification and treatment allocation.
RCT Entities:
BACKGROUND:Rhabdomyosarcoma (RMS) is divided into two major histological subtypes: alveolar (ARMS) and embryonal (ERMS), with most ARMS expressing one of two oncogenic genes fusing PAX3 or PAX7 with FOXO1 (P3F and P7F, respectively). The Children's Oncology Group (COG) carried out a multi-institutional clinical trial to evaluate the prognostic value of PAX-FOXO1 fusion status. METHODS: Study participants were treated on COG protocol D9803 for intermediate risk ARMS or ERMS using multi-agent chemotherapy, radiotherapy, and surgery. Central diagnostic pathology review and molecular testing for fusion genes were carried out on prospectively collected specimens. Event-free (EFS) and overall survival (OS) at 5 years were correlated with histological subtype and PAX-FOXO1 status. RESULTS: Of 616 eligible D9803 enrollees, 434 cases had adequate clinical, molecular, and pathology data for definitive classification as ERMS, ARMS P3F+ or P7F+, or ARMSn (without detectable fusion). EFS was worse for those with ARMS P3F+ (54%) and P7F+ (65%) than those with ERMS (77%; P < 0.001). EFS for ARMSn and ERMS were not statistically different (90% vs. 77%, P = 0.15). ARMS P3F+ had poorer OS (64%) than ARMS P7F+ (87%), ARMSn (89%), and ERMS (82%; P = 0.006). CONCLUSIONS: ARMSn has an outcome similar to ERMS and superior EFS compared to ARMS with either P3F or P7F, when given therapy designed for children with intermediate risk RMS. This prospective analysis supports incorporation of PAX-FOXO1 fusion status into risk stratification and treatment allocation.
Authors: James R Anderson; Frederic G Barr; Douglas S Hawkins; David M Parham; Stephen X Skapek; Timothy J Triche Journal: J Clin Oncol Date: 2010-08-09 Impact factor: 44.544
Authors: Jennifer L Reichek; Fenghai Duan; Lynette M Smith; Donna M Gustafson; Roddy S O'Connor; Chune Zhang; Mandy J Dunlevy; Julie M Gastier-Foster; Frederic G Barr Journal: Clin Cancer Res Date: 2011-01-10 Impact factor: 12.531
Authors: Sabine Stegmaier; Christopher Poremba; Karl-Ludwig Schaefer; Ivo Leuschner; Bernarda Kazanowska; Albert N Békássy; Stefan S Bielack; Thomas Klingebiel; Ewa Koscielniak Journal: Pediatr Blood Cancer Date: 2011-01-19 Impact factor: 3.167
Authors: Elai Davicioni; James R Anderson; Jonathan D Buckley; William H Meyer; Timothy J Triche Journal: J Clin Oncol Date: 2010-02-01 Impact factor: 44.544
Authors: Elai Davicioni; Michael J Anderson; Friedrich Graf Finckenstein; James C Lynch; Stephen J Qualman; Hiroyuki Shimada; Deborah E Schofield; Jonathan D Buckley; William H Meyer; Poul H B Sorensen; Timothy J Triche Journal: Am J Pathol Date: 2009-01-15 Impact factor: 4.307
Authors: Carola A S Arndt; Julie A Stoner; Douglas S Hawkins; David A Rodeberg; Andrea A Hayes-Jordan; Charles N Paidas; David M Parham; Lisa A Teot; Moody D Wharam; John C Breneman; Sarah S Donaldson; James R Anderson; William H Meyer Journal: J Clin Oncol Date: 2009-09-21 Impact factor: 44.544
Authors: Janos Sumegi; Renae Streblow; Robert W Frayer; Paola Dal Cin; Andrew Rosenberg; Aurelia Meloni-Ehrig; Julia A Bridge Journal: Genes Chromosomes Cancer Date: 2010-03 Impact factor: 5.006
Authors: Frederic G Barr; Fenghai Duan; Lynette M Smith; Donna Gustafson; Mandy Pitts; Sue Hammond; Julie M Gastier-Foster Journal: Genes Chromosomes Cancer Date: 2009-08 Impact factor: 5.006
Authors: Simone Hettmer; Zhizhong Li; Andrew N Billin; Frederic G Barr; D D W Cornelison; Alan R Ehrlich; Denis C Guttridge; Andrea Hayes-Jordan; Lee J Helman; Peter J Houghton; Javed Khan; David M Langenau; Corinne M Linardic; Ranadip Pal; Terence A Partridge; Grace K Pavlath; Rossella Rota; Beat W Schäfer; Janet Shipley; Bruce Stillman; Leonard H Wexler; Amy J Wagers; Charles Keller Journal: Cold Spring Harb Perspect Med Date: 2014-11-03 Impact factor: 6.915
Authors: Marielle E Yohe; Christine M Heske; Elizabeth Stewart; Peter C Adamson; Nabil Ahmed; Cristina R Antonescu; Eleanor Chen; Natalie Collins; Alan Ehrlich; Rene L Galindo; Berkley E Gryder; Heidi Hahn; Sharon Hammond; Mark E Hatley; Douglas S Hawkins; Madeline N Hayes; Andrea Hayes-Jordan; Lee J Helman; Simone Hettmer; Myron S Ignatius; Charles Keller; Javed Khan; David G Kirsch; Corinne M Linardic; Philip J Lupo; Rossella Rota; Jack F Shern; Janet Shipley; Sivasish Sindiri; Stephen J Tapscott; Christopher R Vakoc; Leonard H Wexler; David M Langenau Journal: Pediatr Blood Cancer Date: 2019-06-21 Impact factor: 3.167
Authors: Wenyue Sun; Bishwanath Chatterjee; Jack F Shern; Rajesh Patidar; Young Song; Yonghong Wang; Robert L Walker; Bruce R Pawel; Corinne M Linardic; Peter Houghton; Stephen M Hewitt; Daniel C Edelman; Javed Khan; Paul S Meltzer; Frederic G Barr Journal: Int J Cancer Date: 2019-01-15 Impact factor: 7.396
Authors: Michael A Arnold; James R Anderson; Julie M Gastier-Foster; Frederic G Barr; Stephen X Skapek; Douglas S Hawkins; R Beverly Raney; David M Parham; Lisa A Teot; Erin R Rudzinski; David O Walterhouse Journal: Pediatr Blood Cancer Date: 2016-01-12 Impact factor: 3.167
Authors: Pooja Hingorani; Edoardo Missiaglia; Janet Shipley; James R Anderson; Timothy J Triche; Mauro Delorenzi; Julie Gastier-Foster; Michele Wing; Douglas S Hawkins; Stephen X Skapek Journal: Clin Cancer Res Date: 2015-10-15 Impact factor: 12.531
Authors: Kristianne M Oristian; Lisa E S Crose; Nina Kuprasertkul; Rex C Bentley; Yi-Tzu Lin; Nerissa Williams; David G Kirsch; Corinne M Linardic Journal: Cancer Res Date: 2018-08-09 Impact factor: 12.701
Authors: Jack F Shern; Li Chen; Juliann Chmielecki; Jun S Wei; Rajesh Patidar; Mara Rosenberg; Lauren Ambrogio; Daniel Auclair; Jianjun Wang; Young K Song; Catherine Tolman; Laura Hurd; Hongling Liao; Shile Zhang; Dominik Bogen; Andrew S Brohl; Sivasish Sindiri; Daniel Catchpoole; Thomas Badgett; Gad Getz; Jaume Mora; James R Anderson; Stephen X Skapek; Frederic G Barr; Matthew Meyerson; Douglas S Hawkins; Javed Khan Journal: Cancer Discov Date: 2014-01-23 Impact factor: 39.397